RS61685B1 - Kombinacije kompozicija za lečenje poremećaja koji zahtevaju uklanjanje ili uništavanje nepoželjnih ćelijskih razmnožavanja - Google Patents
Kombinacije kompozicija za lečenje poremećaja koji zahtevaju uklanjanje ili uništavanje nepoželjnih ćelijskih razmnožavanjaInfo
- Publication number
- RS61685B1 RS61685B1 RS20210324A RSP20210324A RS61685B1 RS 61685 B1 RS61685 B1 RS 61685B1 RS 20210324 A RS20210324 A RS 20210324A RS P20210324 A RSP20210324 A RS P20210324A RS 61685 B1 RS61685 B1 RS 61685B1
- Authority
- RS
- Serbia
- Prior art keywords
- destruction
- treating disorders
- requiring removal
- combination compositions
- unwanted cellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/738,551 US20160361380A1 (en) | 2015-06-12 | 2015-06-12 | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| EP16730498.9A EP3307299B1 (en) | 2015-06-12 | 2016-06-13 | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| PCT/IB2016/053483 WO2016199112A1 (en) | 2015-06-12 | 2016-06-13 | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61685B1 true RS61685B1 (sr) | 2021-05-31 |
Family
ID=56137476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210324A RS61685B1 (sr) | 2015-06-12 | 2016-06-13 | Kombinacije kompozicija za lečenje poremećaja koji zahtevaju uklanjanje ili uništavanje nepoželjnih ćelijskih razmnožavanja |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160361380A1 (ru) |
| EP (1) | EP3307299B1 (ru) |
| JP (1) | JP6941605B2 (ru) |
| KR (1) | KR20180035788A (ru) |
| CN (1) | CN108135974A (ru) |
| AU (1) | AU2016275368B2 (ru) |
| CA (1) | CA2992174A1 (ru) |
| DK (1) | DK3307299T3 (ru) |
| EA (1) | EA038314B1 (ru) |
| ES (1) | ES2876358T3 (ru) |
| HK (1) | HK1254080A1 (ru) |
| HR (1) | HRP20210462T1 (ru) |
| HU (1) | HUE053665T2 (ru) |
| IL (1) | IL256230B (ru) |
| LT (1) | LT3307299T (ru) |
| MX (1) | MX2017016106A (ru) |
| PL (1) | PL3307299T3 (ru) |
| PT (1) | PT3307299T (ru) |
| RS (1) | RS61685B1 (ru) |
| SI (1) | SI3307299T1 (ru) |
| WO (1) | WO2016199112A1 (ru) |
| ZA (1) | ZA201800083B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10172910B2 (en) * | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) * | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| WO2019055648A1 (en) * | 2017-09-14 | 2019-03-21 | Tufts Medical Center, Inc. | METHOD OF TREATMENT AND DIAGNOSIS OF PROSTATE CANCER |
| US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| US11298400B2 (en) * | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423507A (en) | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3121153A1 (de) | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4775660A (en) | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| US4659695A (en) | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
| FR2582513B1 (fr) | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
| IL101243A (en) | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| WO1994008040A1 (en) | 1992-09-25 | 1994-04-14 | Synaptic Pharmaceutical Corporation | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| US5403847A (en) | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
| EP0790826A4 (en) | 1994-11-16 | 1998-11-11 | Synaptic Pharma Corp | DYHYDROPYRIMIDINE AND THEIR USE |
| DE69941905D1 (de) | 1998-11-10 | 2010-02-25 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| AU2002304314B2 (en) | 2001-03-08 | 2007-09-06 | Nyomox Pharmaceutical Corporation | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| DE60223524D1 (de) * | 2001-05-04 | 2007-12-27 | Nymox Corp | Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine |
| CN1558770A (zh) * | 2001-05-16 | 2004-12-29 | ����Ī�����ɷ�����˾ | 用神经丝状蛋白的区段防止细胞死亡的方法 |
| CA2448348C (en) | 2001-05-25 | 2013-07-16 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| KR101005130B1 (ko) * | 2001-07-19 | 2011-01-04 | 니목스 코포레이션 | 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 |
| CN100432103C (zh) * | 2001-07-19 | 2008-11-12 | 尼莫克斯股份有限公司 | 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽 |
| EP1714979A3 (en) * | 2001-11-16 | 2007-04-25 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US8039511B2 (en) * | 2005-11-15 | 2011-10-18 | Wuxi Jc Pharmaceutical Technology Co., Ltd. | Use of isothiocyanates compounds in treating prostatic diseases and skin cancer |
| ES2400920T3 (es) * | 2006-02-28 | 2013-04-15 | Nymox Corporation | Péptidos eficaces en el tratamiento de tumores y otras afecciones que requieren la eliminación o la destrucción de células |
| JP2009529503A (ja) | 2006-03-10 | 2009-08-20 | ナイモックス コーポレーション | 神経糸状タンパク質由来ペプチドを用いて癌を予防するまたはその危険度または発生率を減少させる方法 |
| EP2672958A1 (en) * | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| EP2970384A1 (en) * | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
-
2015
- 2015-06-12 US US14/738,551 patent/US20160361380A1/en active Pending
-
2016
- 2016-06-13 HU HUE16730498A patent/HUE053665T2/hu unknown
- 2016-06-13 LT LTEP16730498.9T patent/LT3307299T/lt unknown
- 2016-06-13 SI SI201631130T patent/SI3307299T1/sl unknown
- 2016-06-13 ES ES16730498T patent/ES2876358T3/es active Active
- 2016-06-13 EA EA201890045A patent/EA038314B1/ru unknown
- 2016-06-13 WO PCT/IB2016/053483 patent/WO2016199112A1/en active Application Filing
- 2016-06-13 KR KR1020187000969A patent/KR20180035788A/ko not_active Application Discontinuation
- 2016-06-13 MX MX2017016106A patent/MX2017016106A/es unknown
- 2016-06-13 AU AU2016275368A patent/AU2016275368B2/en not_active Ceased
- 2016-06-13 CN CN201680047169.XA patent/CN108135974A/zh active Pending
- 2016-06-13 PT PT167304989T patent/PT3307299T/pt unknown
- 2016-06-13 RS RS20210324A patent/RS61685B1/sr unknown
- 2016-06-13 DK DK16730498.9T patent/DK3307299T3/da active
- 2016-06-13 CA CA2992174A patent/CA2992174A1/en active Pending
- 2016-06-13 JP JP2018516657A patent/JP6941605B2/ja active Active
- 2016-06-13 EP EP16730498.9A patent/EP3307299B1/en active Active
- 2016-06-13 PL PL16730498T patent/PL3307299T3/pl unknown
-
2017
- 2017-12-10 IL IL256230A patent/IL256230B/en active IP Right Grant
-
2018
- 2018-01-05 ZA ZA2018/00083A patent/ZA201800083B/en unknown
- 2018-10-15 HK HK18113144.8A patent/HK1254080A1/zh unknown
-
2021
- 2021-03-19 HR HRP20210462TT patent/HRP20210462T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018517772A (ja) | 2018-07-05 |
| MX2017016106A (es) | 2018-08-01 |
| US20160361380A1 (en) | 2016-12-15 |
| WO2016199112A1 (en) | 2016-12-15 |
| EP3307299A1 (en) | 2018-04-18 |
| LT3307299T (lt) | 2021-04-12 |
| HK1254080A1 (zh) | 2019-07-12 |
| HRP20210462T1 (hr) | 2021-05-14 |
| EA201890045A1 (ru) | 2018-05-31 |
| ZA201800083B (en) | 2019-07-31 |
| AU2016275368B2 (en) | 2022-03-03 |
| HUE053665T2 (hu) | 2021-07-28 |
| CA2992174A1 (en) | 2016-12-15 |
| KR20180035788A (ko) | 2018-04-06 |
| AU2016275368A1 (en) | 2018-02-01 |
| PT3307299T (pt) | 2021-03-26 |
| SI3307299T1 (sl) | 2021-04-30 |
| IL256230A (en) | 2018-02-28 |
| EP3307299B1 (en) | 2020-12-23 |
| IL256230B (en) | 2021-04-29 |
| CN108135974A (zh) | 2018-06-08 |
| ES2876358T3 (es) | 2021-11-12 |
| JP6941605B2 (ja) | 2021-09-29 |
| PL3307299T3 (pl) | 2021-07-05 |
| DK3307299T3 (da) | 2021-03-22 |
| EA038314B1 (ru) | 2021-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254080A1 (zh) | 用於治療需要去除或破壞不需要細胞增殖的病症的組合 | |
| IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
| HK1252741A1 (zh) | 用於治療神經疾病的組合物和方法 | |
| LT3250210T (lt) | Kompozicijos ir būdai, skirti gydyti cns sutrikimus | |
| HUE051488T2 (hu) | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére | |
| SG11201701504WA (en) | Compositions and methods for treatment of neurological disorders | |
| ME03749B (me) | KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a | |
| IL260352B (en) | Methods and preparations for the treatment of neurological disease | |
| IL259861A (en) | Methods and preparations for the treatment of disorders related to seizures | |
| HK1258696A1 (zh) | 治療或預防皮膚障礙的新型組合物和方法 | |
| ZA201801214B (en) | Compositions and methods for treatment of stroke and other cns disorders | |
| EP3303556C0 (en) | COMPOSITIONS FOR THE TREATMENT OF OSTEO-CARTILAGINOUS DISORDERS | |
| HK1256298A1 (zh) | 用於治療和預防神經退化性病症的組合物和方法 | |
| EP3262065C0 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| IL258629A (en) | Methods and preparations for the treatment of traumatic brain damage |